BIOGEN INC. Payments to Acquire Available-for-sale Securities
BIOGEN INC. (BIIB) reported Payments to Acquire Available-for-sale Securities of $5.25 billion for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2020-02-06
- BIOGEN INC. payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $1.92B, a 52.72% increase year-over-year.
- BIOGEN INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $1.26B, a 44.72% decline year-over-year.
- BIOGEN INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $1.56B, a 13.37% decline year-over-year.
- BIOGEN INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $1.28B, a 33.33% decline year-over-year.
- BIOGEN INC. payments to acquire available-for-sale securities for fiscal 2019 was $5.25B, a 31.74% decline from fiscal 2018.
- BIOGEN INC. payments to acquire available-for-sale securities for fiscal 2018 was $7.69B, a 43.69% increase from fiscal 2017.
- BIOGEN INC. payments to acquire available-for-sale securities for fiscal 2017 was $5.36B, a 32.33% decline from fiscal 2016.
- BIOGEN INC. payments to acquire available-for-sale securities for fiscal 2016 was $7.91B, a 15.27% increase from fiscal 2015.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 3 month as first filed | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 6 month as first filed | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 9 month as first filed | Payments to Acquire Available-for-sale Securities 12 month | Payments to Acquire Available-for-sale Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2019-12-31 | $5.25B 10-K · filed 2020-02-06 | |||||||
| 2018-12-31 | $7.69B 10-K · filed 2020-02-06 | |||||||
| 2018-03-31 | $1.92B 10-Q · filed 2018-04-24 | $3.18B derived: sum of 2 quarters · filed 2020-02-06 | $4.74B derived: sum of 3 quarters · filed 2020-02-06 | $6.02B derived: sum of 4 quarters · filed 2020-02-06 | ||||
| 2017-12-31 | $1.26B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $2.82B derived: sum of 2 quarters · filed 2020-02-06 | $4.10B derived: sum of 3 quarters · filed 2020-02-06 | $5.36B 10-K · filed 2020-02-06 | ||||
| 2017-09-30 | $1.56B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $2.84B derived: sum of 2 quarters · filed 2017-10-24 | $4.09B 10-Q · filed 2017-10-24 | $6.38B derived: sum of 4 quarters · filed 2019-02-06 | ||||
| 2017-06-30 | $1.28B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $2.54B 10-Q · filed 2017-07-25 | $4.82B derived: sum of 3 quarters · filed 2019-02-06 | $6.62B derived: sum of 4 quarters · filed 2019-02-06 | ||||
| 2017-03-31 | $1.26B 10-Q · filed 2018-04-24 | $3.54B derived: sum of 2 quarters · filed 2019-02-06 | $5.34B derived: sum of 3 quarters · filed 2019-02-06 | $7.26B derived: sum of 4 quarters · filed 2019-02-06 | ||||
| 2016-12-31 | $2.28B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $4.08B derived: sum of 2 quarters · filed 2019-02-06 | $6.00B derived: sum of 3 quarters · filed 2019-02-06 | $7.91B 10-K · filed 2019-02-06 | ||||
| 2016-09-30 | $1.80B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $3.72B derived: sum of 2 quarters · filed 2017-10-24 | $5.63B 10-Q · filed 2017-10-24 | $7.63B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-06-30 | $1.92B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $3.83B 10-Q · filed 2017-07-25 | $5.83B derived: sum of 3 quarters · filed 2018-02-01 | $8.65B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2016-03-31 | $1.91B 10-Q · filed 2017-04-25 | $3.91B derived: sum of 2 quarters · filed 2018-02-01 | $6.73B derived: sum of 3 quarters · filed 2018-02-01 | $8.46B derived: sum of 4 quarters · filed 2018-02-01 | ||||
| 2015-12-31 | $1.99B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $4.82B derived: sum of 2 quarters · filed 2018-02-01 | $6.54B derived: sum of 3 quarters · filed 2018-02-01 | $6.86B 10-K · filed 2018-02-01 | ||||
| 2015-09-30 | $2.83B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | $4.55B derived: sum of 2 quarters · filed 2016-10-26 | $4.87B 10-Q · filed 2016-10-26 | $4.87B 10-Q · filed 2015-10-21 | $5.71B derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-06-30 | $1.72B derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-21 | $2.04B 10-Q · filed 2016-07-21 | $2.05B 10-Q · filed 2015-07-24 | $2.89B derived: sum of 3 quarters · filed 2017-02-02 | $3.84B derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2015-03-31 | $323.00M 10-Q · filed 2016-04-21 | $322.96M 10-Q · filed 2015-04-24 | $1.17B derived: sum of 2 quarters · filed 2017-02-02 | $2.12B derived: sum of 3 quarters · filed 2017-02-02 | $3.24B derived: sum of 4 quarters · filed 2017-02-02 | |||
| 2014-12-31 | $844.52M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $1.80B derived: sum of 2 quarters · filed 2017-02-02 | $2.92B derived: sum of 3 quarters · filed 2017-02-02 | $3.58B 10-K · filed 2017-02-02 | $3.58B 10-K · filed 2015-02-04 | |||
| 2014-09-30 | $950.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $2.07B derived: sum of 2 quarters · filed 2015-10-21 | $2.74B 10-Q · filed 2015-10-21 | $3.54B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-06-30 | $1.12B derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | $1.79B 10-Q · filed 2015-07-24 | $2.59B derived: sum of 3 quarters · filed 2016-02-03 | $3.45B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2014-03-31 | $666.21M 10-Q · filed 2015-04-24 | $1.47B derived: sum of 2 quarters · filed 2016-02-03 | $2.33B derived: sum of 3 quarters · filed 2016-02-03 | $2.78B derived: sum of 4 quarters · filed 2016-02-03 | ||||
| 2013-12-31 | $804.49M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $1.66B derived: sum of 2 quarters · filed 2016-02-03 | $2.12B derived: sum of 3 quarters · filed 2016-02-03 | $3.28B 10-K · filed 2016-02-03 | $3.28B 10-K · filed 2014-02-06 | |||
| 2013-09-30 | $855.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-22 | $1.31B derived: sum of 2 quarters · filed 2014-10-22 | $2.47B 10-Q · filed 2014-10-22 | $3.62B derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-06-30 | $457.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $1.62B 10-Q · filed 2014-07-23 | $2.76B derived: sum of 3 quarters · filed 2015-02-04 | $3.70B derived: sum of 4 quarters · filed 2015-02-04 | ||||
| 2013-03-31 | $1.16B 10-Q · filed 2014-04-23 | $2.30B derived: sum of 2 quarters · filed 2015-02-04 | $3.24B derived: sum of 3 quarters · filed 2015-02-04 | |||||
| 2012-12-31 | $1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $2.08B derived: sum of 2 quarters · filed 2015-02-04 | $3.33B 10-K · filed 2015-02-04 | |||||
| 2012-09-30 | $938.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $2.19B 10-Q · filed 2013-10-28 | ||||||
| 2012-06-30 | $1.25B 10-Q · filed 2013-07-25 | |||||||
| 2011-12-31 | $3.70B 10-K · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |